It can be competitive to get the best deal — but retailers' math can have you scratching your head. How do you get a good deal?» Read More
Why we will have easy monetary policy for some time.
Some of the biggest tech names reported strong results in the third quarter, but some still face an uphill battle, analyst suggest.
European stocks continued to rally on Friday, and one trader says that's only one of many reasons to buy right now.
Some of the names on the move ahead of the open.
Stephanie Link, whose CNBC "Halftime Report" model portfolio is up 7 percent this year, believes shares of Lam Research are poised to rise.
If investors look to Europe amid easy monetary policy, consumer-facing names may provide the best upside, two experts said.
While headlines are dominated by the debate over drug pricing and business models, the real issue for healthcare may be that business is slowing.
Drugmaker Valeant is in dire need of a total leadership turnover, said former Medtronic CEO Bill George on Thursday.
Lumber Liquidators pleaded guilty to environmental crimes and agreed to pay $13.2 million, reports CNBC's Tyler Mathisen.
President Obama vetoed a $612 billion defense policy bill and asked for improvements, reports CNBC's Sue Herera.
CNBC's Michelle Caruso Cabrera provides a preview of tonight's CNBC special on entertainer, entrepreneur and Latin hero, Pitbull.
A technical forecast for the Russell 2000, with Matt Maley, Miller Tabak & Co. managing director.
Looking ahead to earnings from Alphabet, Amazon and Microsoft, with Paul Meeks, Saturna Capital portfolio manager and tech analyst. Saturna owns all three names.
CNBC's Josh Lipton reports the important metrics to watch in Amazon, Alphabet and Microsoft earnings.
Shares of GNC are under pressure after a halt when a lawsuit accused GNC of selling drug-spiked dietary supplements, reports CNBC's Brian Sullivan.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including Stifel raising estimates on Asbury Automotive's quarter.
Hedge funds are getting hurt after Citron Research released a report bringing Valeant's business practices into question, with CNBC's Kate Kelly.
Citron Research released a report accusing Valeant of inflating sales numbers through dubious business practices. Discussing the best scenario for Valeant and shareholders, with Peter Andersen, Congress Wealth Management CIO.
Shares of GNC are under pressure after a lawsuit accusing GNC of selling drug-spiked dietary supplements, reports CNBC's Sue Herera.
CNBC's Meg Tirrell reports a number of health groups have appealed to Turing Pharmaceuticals asking the company to lower its drug price of Daraprim.